Related Experiment Video
Updated: Jul 16, 2026
08:35
Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
The Bcl-2 apoptotic switch in cancer development and therapy
1Department of Molecular Genetics of Cancer, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria 3050, Australia. adams@wehi.edu.au
Oncogene
|February 27, 2007
Summary
Impaired apoptosis, crucial in cancer, involves Bcl-2 family interactions. Understanding these proteins aids cancer therapy and the development of BH3 mimetics drugs.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- Impaired apoptosis contributes to cancer development and treatment resistance.
- The Bcl-2 protein family regulates apoptosis through interactions between pro-survival and BH3-only proteins.
Purpose of the Study:
- To elucidate the regulatory mechanisms of apoptosis controlled by the Bcl-2 protein family.
- To explore the role of Bcl-2 family interactions in cancer and their implications for therapy.
Main Methods:
- Analysis of protein-protein interactions within the Bcl-2 family.
- Investigating the signaling pathways of BH3-only proteins in response to cellular damage.
Main Results:
- BH3-only proteins initiate apoptosis by engaging pro-survival Bcl-2 family members.
- The balance of Bcl-2 family proteins is critical for tissue homeostasis; dysregulation can be oncogenic.
- Activation of Bax and Bak is triggered by BH3-only proteins engaging multiple pro-survival proteins.
Conclusions:
- Understanding Bcl-2 family dynamics clarifies cancer development and conventional therapy mechanisms.
- Targeting Bcl-2 family interactions with BH3 mimetics represents a promising anticancer drug strategy.
Related Concept Videos
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
01:22Cellular Injury V: Apoptosis and Autophagy
Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...
01:17The Extrinsic Apoptotic Pathway
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...